BGNE US07725L1026

Report

Delayed Nasdaq - 04:00:00 2023-02-01 pm EST
254.28	USD		-0.67%

02/01	BeiGene to Present at Upcoming Investor Conferences	BU
01/31	Beigene, Ltd. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
01/24	Morgan Stanley Adjusts Price Target on BeiGene to $325 From $295, Maintains Overweight Rating	MT

Analyst Recommendations on BEIGENE, LTD.

01/24	Morgan Stanley Adjusts Price Target on BeiGene to $325 From $295, Maintains Overweight ..	MT
01/20	Guggenheim Raises Price Target on BeiGene to $350 From $290, Maintains Buy Rating	MT
01/20	SVB Securities Adjusts Price Target on BeiGene to $300 From $236, Maintains Outperform ..	MT
2022	SVB Securities Adjusts BeiGene Price Target to $236 From $210, Maintains Outperform Rat..	MT
2022	SVB Securities Adjusts Price Target on BeiGene to $210 From $200, Maintains Outperform ..	MT
2022	Nomura Adjusts BeiGene Price Target to $281.78 From $286.31, Maintains Buy Rating	MT
2022	Nomura Adjusts Beigene's Price Target to HK$170.15 From HK$172.89, Keeps at Buy	MT
2022	Morgan Stanley Raises BeiGene's Price Target to $295 From $290, Maintains Overweight Ra..	MT
2022	Guggenheim Upgrades BeiGene to Buy From Neutral; Price Target is $205	MT
2022	SVB Securities Upgrades BeiGene to Outperform From Market Perform, Adjusts Price Target..	MT
2022	JPMorgan Assumes BeiGene at Overweight with $296 Price Target	MT
2022	Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating	MT
2022	Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy	MT
2022	Analyst recommendations: Eli Lilly, KLA, Kellogg, Epam Systems, ..
2022	Nomura Adjusts BeiGene's Price Target to $277.35 From $310.62, Maintains Buy Rating	MT
2022	Nomura Adjusts Beigene's Price Target to HK$167.48 From HK$186.85, Keeps at Buy	MT
2022	Morgan Stanley Adjusts BeiGene's Price Target to $293 from $300, Keeps Overweight Ratin..	MT
2022	Morgan Stanley Adjusts Price Target for BeiGene to $293 From $300, Maintains Overweight..	MT
2022	CMB International Starts BeiGene at Buy With $248.52 Price Target	MT
2022	Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..	MT
2022	Morgan Stanley Adjusts BeiGene's Price Target to $338 from $330, Keeps Overweight Ratin..	MT
2022	SVB Leerink Cuts BeiGene to Market Perform From Outperform, Price Target to $177 From $..	MT
2022	Nomura Upgrades BeiGene to Buy From Neutral, Adjusts Price Target to $310.62 From $293...	MT
2022	Nomura Upgrades BeiGene to Buy From Neutral, Adjusts Price Target to HK$186.85 From HK$..	MT
2022	Macquarie Lowers BeiGene's Price Target to $301.60 From $312.80, Maintains Outperform R..	MT
2022	Morgan Stanley Lowers BeiGene's Price Target to $330 From $360, Maintains Overweight Ra..	MT
2022	Goldman Sachs Lowers BeiGene's Price Target to $364.32 From $410.60, Maintains Buy Rati..	MT
2022	SVB Leerink Adjusts BeiGene's Price Target to $300 from $334, Maintains Outperform Rati..	MT
2022	Morgan Stanley Adjusts BeiGene's Price Target to $360 from $407, Keeps Overweight Ratin..	MT
2021	Nomura Adjusts BeiGene's Price Target to $293.28 From $355.83, Maintains Neutral Rating	MT
2021	Nomura Adjusts Beigene's Price Target to HK$176.97 From HK$214.05, Keeps at Neutral	MT
2021	Nomura Adjusts BeiGene to Neutral From Not Rated, Sets $355.83 Price Target	MT
2021	BeiGene : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintai..	MT
2021	BeiGene : Bernstein Starts BeiGene at Outperform With $431 Price Target	MT
2021	BeiGene : Morgan Stanley Adjusts Price Target on BeiGene to $407 From $409, Main..	MT
2021	BeiGene : SVB Leerink Adjusts BeiGene's Price Target to $417 from $388, Keeps Ou..	MT
2021	BeiGene : Morgan Stanley Adjusts Price Target on BeiGene to $409 From $357, Main..	MT
2021	BeiGene : Morgan Stanley Adjusts BeiGene's Price Target to $357 from $375, Keeps..	MT
2021	BeiGene : HSBC Adjusts BeiGene's Price Target to $385 from $296, Keeps Buy Ratin..	MT
2021	BeiGene : China Renaissance Initiates Coverage on BeiGene With Buy Rating	MT
2021	BeiGene : CLSA Downgrades BeiGene to Underperform From Outperform, Adjusts Price..	MT
2021	BeiGene : Cowen & Co. Adjusts Price Target on BeiGene to $429 From $348, Maintai..	MT
2021	BeiGene : Morgan Stanley Adjusts BeiGene PT to $375 From $310, Maintains Overwei..	MT
2020	BeiGene : Ladenburg Thalmann Upgrades BeiGene to Buy From Neutral; Price Target ..	MT
2020	BeiGene : SVB Leerink Adjusts BeiGene's Price Target to $327 From $240, Keeps at..	MT
2020	BeiGene : Morgan Stanley Adjusts BeiGene PT to $310 From $270, Maintains Overwei..	MT
2020	BeiGene : Ladenburg Thalmann Downgrades BeiGene to Neutral from Buy	MT
2020	BeiGene : Piper Sandler Downgrades BeiGene to Underweight From Neutral; Price Ta..	MT

Analysis

China-focused hedge funds lower exposure as risks mount